Skip to main content

Resource Library for GORE® VIABIL® Short Wire Biliary Endoprosthesis

Narrow by

ENDO_GORE® VIABIL® BILIARY ENDOPROSTHESIS BARON CASE STUDY - U.S.

Case study with photos of ERCP procedure using GORE® VIABIL® Biliary Endoprosthesis for biliary malignant obstruction

PDF, 861.98 KB

Resource image

ENDO_GORE® VIABIL® Biliary Endoprosthesis Anti-Migration Assurance Program

Only applicable to Gore® VIABIL® delivered endoscopically. Not applicable to VIABIL® devices for percutaneous delivery. Gore's Anti-Migration Assurance Program offered through ConMed.

PDF, 529 KB

Resource image

ENDO_GORE® VIABIL® Biliary Endoprosthesis Clinical Summary - ConMed Logo

2017 Clinical performance summary of VIABIL in the treatment of malignant strictures. Co-branded GORE/CONMED Endoscopic

PDF, 603 KB

ENDO_GORE® VIABIL® Biliary Endoprosthesis Remains Patent at 266 Days

Case study - ePTFE/FEP covered stent-graft VIABIL® provided long-term palliation for jaundice caused by malignant obstruction of the common bile duct.

PDF, 534.26 KB

ENDO_GORE® VIABIL® Brochure - CONMED

Focused on VIABIL® Short Wire for Endoscopic delivery; Maximize control, minimize migrations. Endoscopic device distributed in the US and Canada by ConMed

PDF, 2.74 MB

GORE® VIABIL® Biliary Endoprosthesis Yedavalli Case Study: decreased resistance to bile flow

GORE® VIABIL® Biliary Endoprosthesis case study – one of two from Dr. Yedavalli in 2023. It presents a successful resolution of malignant biliary obstruction of the common bile duct with normalization of serum bilirubin and decreased pain.

PDF, 1.75 MB

GORE® VIABIL® Biliary Endoprosthesis Yedavalli Case Study: mitigation of stent migration concerns

GORE® VIABIL® Biliary Endoprosthesis case study – one of two from Dr. Yedavalli in 2023. It presents a successful resolution of high grade distal malignant biliary obstruction of the common bile duct.

PDF, 2 MB

PERC_GORE® VIABIL® Biliary Endoprosthesis - Brochure for Percutaneous Delivery, NA

North-American version. VIABIL Brochure for percutaneous delivery. New migration data demonstrates once again VIABIL's low migration rates.

PDF, 3.16 MB